Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G.0660.09)
Onderzoeksraad, KU Leuven (OT/08/056, OT/12/097)
Stichting Alzheimer Onderzoek (09013, 11020, 13007)
Vlaams Agentschap voor Onderzoek en Innovatie (135043)
Received: 27 November 2020
Accepted: 22 February 2021
First Online: 7 April 2021
Ethics approval and consent to participate
: The protocol was approved by the Ethics Committee University Hospitals Leuven. Written informed consent was obtained from all subjects in accordance with the Declaration of Helsinki.
: Not applicable.
: None of the authors report disclosures relevant to the manuscript, except RV. RV has received research grants from Research Foundation - Flanders (FWO) and KU Leuven, has had a clinical trial agreement for phase 1 and 2 study between University Hospitals Leuven and GEHC, has received a non-financial support from GEHC (provision of <sup>18</sup>F-flutemetamol for conduct of investigator-driven trial free of cost) and has a clinical trial agreement (local principal investigator) between University Hospitals Leuven and Merck, Forum, Roche.